{"organizations": [], "uuid": "2844291d886c41e8f054aa38eb0c55074fb3d2e5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/UKHealthNews/", "section_title": "Reuters: Health News", "url": "https://uk.reuters.com/article/us-johnson-johnson-study-alzheimers/johnson-johnson-scraps-alzheimers-trials-on-safety-concerns-idUKKCN1IJ2BC", "country": "US", "domain_rank": 408, "title": "Johnson & Johnson scraps Alzheimer's trials on safety concerns", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-18T20:04:00.000+03:00", "replies_count": 0, "uuid": "2844291d886c41e8f054aa38eb0c55074fb3d2e5"}, "author": "", "url": "https://uk.reuters.com/article/us-johnson-johnson-study-alzheimers/johnson-johnson-scraps-alzheimers-trials-on-safety-concerns-idUKKCN1IJ2BC", "ord_in_thread": 0, "title": "Johnson & Johnson scraps Alzheimer's trials on safety concerns", "locations": [], "entities": {"persons": [{"name": "johnson", "sentiment": "none"}, {"name": "janssen", "sentiment": "none"}], "locations": [], "organizations": [{"name": "johnson & johnson", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "merck and co inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 18, 2018 / 5:05 PM / Updated 23 minutes ago Johnson & Johnson scraps Alzheimer's trials on safety concerns Reuters Staff 2 Min Read\n(Reuters) - Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer’s drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease.\nSome trial participants showed serious elevations of liver enzymes and the company concluded that the benefit-risk ratio offered by the drug, atabecestat, no longer supported its development, said Janssen, a unit of Johnson and Johnson.\nAtabecestat belongs to a class of experimental Alzheimer’s drugs called BACE inhibitors that block an enzyme involved in the production of a protein that creates brain plaques, which are considered a major cause for the disease.\nAnalysts expect the successful development of a treatment for the disease, which affects about 5.7 million Americans, to virtually guarantee multi-billion dollar annual sales.\nHowever, several drugmakers, including Pfizer Inc, Merck and Co Inc, have been forced to abandon trials over lack of effectiveness or safety concerns.\nEli Lilly & Co and AstraZeneca Plc are testing their BACE inhibitor, lanabecestat, in late-stage trials and are due to report results next year.\nJohnson & Johnson was testing atabecestat to slow cognitive decline in certain patients identified to be progressing to Alzheimer’s dementia. Reporting by Tamara Mathias in Bengaluru; Additional reporting by Julie Steenhuysen in Chicago; Editing by Sriraj Kalluvila", "external_links": [], "published": "2018-05-18T20:04:00.000+03:00", "crawled": "2018-05-18T20:35:19.022+03:00", "highlightTitle": ""}